Lâle White, CEO and founder of XIFIN, is dedicated to the vision of optimizing the economics of healthcare – creating an environment in which patients receive the best healthcare at the lowest cost to themselves and the healthcare system as a whole. Since founding the company in 1997, she has helped diagnostic labs and health systems process more than 70 million lab visits per year, realizing more than $3 billion in cumulative net cash collection gains.
Lâle is a nationally recognized expert in the field of medical financial management and regulatory compliance, with over 35 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major labs and lab associations throughout the U.S. She has chaired the state and federal contractor committees for California Clinical Laboratory Association (CCLA), maintaining a working relationship with the Department of Health and Human Services. Lâle has also worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program.
Prior to founding XIFIN, Lâle held leadership roles with Laboratory Corporation of America and National Health Laboratories. She has held Board of Directors memberships with bioTheranostics while it was a BioMerieux subsidiary, and CombiMatrix Corporation, until its acquisition by Invitae Corporation in 2017; and is currently on the board of Cardiff Oncology and NoniGenex.
Lâle has been recognized with multiple industry and business honors including the lifetime achievement award from the CCLA, the Entrepreneur of the Year Award from Ernst & Young and inclusion in the Top 50 Women Entrepreneurs in America from Inc. She has a BA in finance and an MBA from Florida International University.